Kininogen I Cleavage Detection for Lung Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor markers for lung cancer, such as CEA, CYFRA 21-1, and NSE, have low sensitivity, especially for early stages and non-small cell lung cancer, making them inadequate for effective detection and diagnosis.
Innovation Solution
A method for detecting lung cancer through the analysis of abnormal cleavage products of kininogen I in body fluids, such as urine and blood, using specific protein fragments like ESNEELTESCET, IYPTVNCQPLG, TEHLASSSEDSTTPSA, IYPTVNCQPLGMIS, IYPTVNCQPL, and IYPTVNCQP, employing mass spectrometric, immunochemical, or chromatographic methods to determine fragmentation rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing tumor markers (CEA, CYFRA 21-1, NSE) are used for lung cancer detection, then the detection method is simple and widely available, but the sensitivity is low especially for early stages and non-small cell lung cancer
Solution Approach 1:
The patent changes the detection parameter from conventional tumor markers (CEA, CYFRA 21-1, NSE) to a new biomarker (UBE2L3 protein or its nucleic acid). This parameter change achieves higher sensitivity for early-stage and non-small cell lung cancer detection while maintaining clinical applicability through standardized testing procedures
2Measurement precision
If invasive tumor markers requiring blood drawing are used, then the detection sensitivity can be improved, but the invasiveness and patient discomfort increase
Solution Approach 1:
The patent uses UBE2L3 biomarker which can be detected through minimally invasive methods such as analyzing body fluids (urine, saliva, breath condensate) that contain copies or traces of the tumor-associated protein or its nucleic acid. This copying approach allows sensitive detection without requiring invasive blood drawing
3Measurement precision
If conventional tumor markers are used for early lung cancer detection, then the examination is simple, but the positive detection rate is significantly decreased
Solution Approach 1:
The patent enables preliminary detection of early-stage lung cancer by establishing a screening method using UBE2L3 biomarker that can identify cancer at stage I with high sensitivity. This preliminary action allows early intervention before the disease progresses to later stages, preventing diagnosis delay and improving patient outcomes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for a minimally invasive and highly sensitive detection of lung cancer, including early stages and recurrence, with improved diagnostic accuracy compared to existing markers, using easily accessible body fluids.
Implementation Method 1
employing mass spectrometric, immunochemical, or chromatographic methods to determine fragmentation rates
Implementation Method 2
employing mass spectrometric, immunochemical, or chromatographic methods to determine fragmentation rates
Implementation Method 3
employing mass spectrometric, immunochemical, or chromatographic methods to determine fragmentation rates
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided is a lung adenocarcinoma detection method that is simple and is less invasive. The lung adenocarcinoma detection method of the present invention includes the step of detecting the presence or absence of an abnormal cleavage in kininogen I in a sample collected from a subject in vitro. The abnormal cleavage in kininogen I is, for example, a cleavage that can form at least one cleaved site in a peptide bond in kininogen I and/or a cleavage that causes the deletion of at least one amino acid residue at least one site in kininogen I. The lung adenocarcinoma detection method according to the present invention includes the step of detecting the presence or amount of a protein having the above-mentioned abnormal cleavage or the loss of the amount of a normal protein, and the like.